Uniqure B.V. Aktie [WKN DE: A1XDTV / ISIN: NL0010696654]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Uniqure B.V.

22.06.21		uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update (GlobeNewswire)
22.06.21		uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) (GlobeNewswire)
16.06.21		uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
02.06.21		uniQure to Participate in Multiple Upcoming Industry Conferences in June (GlobeNewswire)
27.05.21		uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
13.05.21		uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector (GlobeNewswire)
10.05.21		uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
06.05.21		uniQure announces closing of commercialization and license agreement with CSL Behring (GlobeNewswire)
03.05.21		uniQure to Participate in Multiple Upcoming Industry Conferences in May (GlobeNewswire)
28.04.21		uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
26.04.21		uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program (GlobeNewswire)
08.04.21		uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain (GlobeNewswire)
05.04.21		uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
01.04.21		uniQure to Participate in Multiple Upcoming Industry Conferences in April (GlobeNewswire)
29.03.21		uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program (GlobeNewswire)
01.03.21		uniQure Announces 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
26.02.21		uniQure to Participate in Multiple Upcoming Industry Conferences in March (GlobeNewswire)
09.02.21		ATHE Gets Funded For Parkinson's Research, No Safety Issues For QURE's Trial, TNXP On Watch (RTTNews)
08.02.21		uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
01.02.21		uniQure to Participate in Multiple Upcoming Industry Conferences in February (GlobeNewswire)
22.12.20		NantKwest Stock Goes North, QURE's HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine (RTTNews)
21.12.20		uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program (GlobeNewswire)
08.12.20		uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematolo (GlobeNewswire)
07.12.20		uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B (GlobeNewswire)
02.12.20		uniQure to Participate in Multiple Upcoming Industry Conferences in December (GlobeNewswire)
30.11.20		uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
20.11.20		AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B (RTTNews)
19.11.20		uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B (GlobeNewswire)
04.11.20		uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
04.11.20		uniQure to Participate in Multiple Upcoming Industry Conferences in November (GlobeNewswire)
27.10.20		uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
13.10.20		uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
30.09.20		uniQure to Participate in Multiple Upcoming Industry Conferences in October (GlobeNewswire)
25.09.20		uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
03.09.20		uniQure to Participate in Multiple Upcoming Industry Conferences in September (GlobeNewswire)
26.08.20		uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development (GlobeNewswire)
30.07.20		uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
25.06.20		Stock Alert: UniQure Down 20% (RTTNews)
25.06.20		CSL Behring To Buy Late-Stage Gene Therapy Candidate For Hemophilia B Patients From UniQure (RTTNews)
24.06.20		uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy (GlobeNewswire)
19.06.20		uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
17.06.20		uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors (GlobeNewswire)
15.06.20		uniQure Announces Change for its 2020 Annual General Meeting of Shareholders (GlobeNewswire)
14.05.20		uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting (GlobeNewswire)
29.04.20		uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
28.04.20		uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting (GlobeNewswire)
17.04.20		uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors (GlobeNewswire)
30.03.20		uniQure to Participate in Multiple Upcoming Investor Conferences in April (GlobeNewswire)
02.03.20		uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters (GlobeNewswire)
27.02.20		uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference (GlobeNewswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Krypto-Influencer prognostiziert für 2025 gewaltige Rally beim Dogecoin

Solana Kurs-Prognose: 300 US-Dollar noch im Januar?

Pierer Mobility-Aktie knickt ein: KTM wird Produktionsstopp womöglich verlängern

Zinspolitik 2025: EZB plant Senkungen - wie schnell kommen sie?

Tesla-Aktie sackt ab: Absatzzahlen bleiben hinter Erwartungen

Apple-Aktie unter Druck: Apple kämpf offenbar mit China-Konkurrenz

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.01.2025 17:36
Kaufwert:	EUR
	Hinzufügen Speichern